Category Archives: healthcare

Why was Measles added to the list of quarantinable diseases?

The Demented Puppet has signed a (putative) executive order, adding measles to the list of quarantinable diseases.

The quarantine laws allow all levels of governments to isolate, separate, and restrict movement of sick persons and those who were in their proximity. Except for COVID-19 and pandemic flu, this quarantinable diseases list only included very rare and dangerous infectious diseases such as Cholera, Diphtheria, Infectious Tuberculosis, Plague, Smallpox, Yellow fever, viral hemorrhagic fevers (Ebola and similar), severe acute respiratory syndromes (SARS, MERS). Each disease on the list is either highly lethal or epidemic, and most of them are both. Continue reading Why was Measles added to the list of quarantinable diseases?

FDA Fiction — Fictional Approval of COVID-19 Vaccine

As many have correctly noticed, the FDA has not approved any of the COVID-19 vaccines. All currently used Covid-19 vaccines are still under Emergency Use Authorization (EUA). So, the obvious questions are:

  1. Has the FDA approved the BioNTech COMIRNATY vaccine, as alleged?
  2. Why would the FDA approve a vaccine not supplied to the US, instead of approving the equivalent formulation, manufactured and distributed by Pfizer[1], which has been injected in half of the US population, allegedly with enormous success?
  3. Finally, why has the FDA created an artificial legal distinction[2] between batches of the same product, manufactured at different plants?

The FDA Approval Letter in the question is dated by August 23 and is signed by two directors of CBER offices. One of those directors is Marion Gruber, PhD, who has announced her future resignation, due to the CDC’s attempts to force an approval of a COVID-19 vaccine. Continue reading FDA Fiction — Fictional Approval of COVID-19 Vaccine

Current COVID-19 vaccines are obsolete

All currently circulating strains of SARS-COV-2 (i.e., Delta sub-variants) have spike mutations L452R & T478K, disabling most vaccine induced antibodies. These strains also have aT19R mutation, disrupting epitopes in spike NTD. Many NTD-directed antibodies are known to cause ADE, especially when the epitopes which they target are disrupted.

These L452R/Q & T478K have been mutations of concern for many months. Pfizer & Moderna have had plenty of time to modify their vaccines and/or make a booster with the new spike mRNA. Surprisingly however, the Biden-Harris regime has not demanded any modifications to improve the vaccine to make it effective against the current SARS-COV-2 variants.

All the side effects and other harms remain.

Medical hypothesis about the evolving Delta variant and its early treatment

2021-09-09,  preprint, self-published Cochrane-style. TreatingEvolvingDelta-Zinc.PDF 

Bullet Points
  • The current coronavirus variant has a shorter incubation period and a higher replication rate than previous variants. This necessitates an earlier start of anti-viral treatment despite the efforts of certain forces to hinder access to the necessary medications.
  • The current coronavirus variant is capable of cell-cell fusion. This may decrease the effectiveness of antibodies and some drugs. One way to compensate for this is with higher amounts of zinc and its ionophores, especially hydroxychloroquine.

Continue reading Medical hypothesis about the evolving Delta variant and its early treatment

Delta Subvariants AY.3, AY.4, and A.25 are Dominant. The CDC Lies.

2021-10-17: OBSOLETE, except that the CDC continues to lie. See Delta Growth for updated information.

2021-09-06: updated with the sub-variant AY.25. The situation is changing rapidly. This article is not being updated

The CDC uses W.H.O’s classification of the SARS-COV2 variants. W.H.O has failed to elevate Delta sub-variants into full variants when such a classification is more than warranted. Consequently, what has been called Delta (B.1.617.2) since May 2021 is a mix of many sub-variants with different properties. This confused clinicians and the CDC added to this confusion. Continue reading Delta Subvariants AY.3, AY.4, and A.25 are Dominant. The CDC Lies.

Importance of Oral and Nasal Hygiene in COVID-19 Pandemic

We are constantly reminded to wash our hands with soap or alcoholic solutions that kill the coronavirus. But the coronavirus does not live on hands. COVID-19 starts in the upper respiratory tract (URT). The largest load develops in the nasopharynx. From there, it spreads into the lungs through the pharynx mucosal surfaces. Therefore, it stands to reason that we should frequently cleanse the upper respiratory tract: nasal cavity, oral cavity, nasopharynx, and oropharynx. The most promising antiseptic is Povidone-Iodine (PVP-I), because it has been used for this purpose in dentistry and otolaryngology for decades. Continue reading Importance of Oral and Nasal Hygiene in COVID-19 Pandemic

C19 Vaccines are not for Immune Persons. Prophylaxis before C19 Vaccine? Mucosal Immunity?

C19 Vaccines were not formulated for people who have recovered from COVID-19

The clinical trials for the mRNA vaccines excluded participants who were seropositive for COVID-19. Thus, the trials safety and efficacy results are applicable only to individuals seronegative for COVID-19 antibodies. Seropositive persons already have antibodies to COVID-19 and are therefore likely immune.  Thus, they do not need the mRNA vaccine and they are likely to have stronger adverse effects from vaccination.

Based on the CDC’s own data, most people <65 who receive are now being vaccinated already have natural immunity.

Antiviral Prophylaxis with Vaccine?

2021-08-26. Vaccination decreases innate immunity for some time after the each shot. For COVID-19 in adults, this decrease in the innate immunity is likely compensated by the vaccine-elicited adaptive immunity. This compensation might become sufficiently effective as soon as 10 days after the first shot, although some estimates are longer.

COVID-19 vaccination is conducted in areas where the disease is present, and the person might be already infected in time of vaccination, or become infected within those 10 days. Notice that the vaccine elicited immunity is less effective against the Delta variant, and is likely to be even less effective against future variants. Continue reading C19 Vaccines are not for Immune Persons. Prophylaxis before C19 Vaccine? Mucosal Immunity?

The Health Harms and Risks of Face Masks

August 23, 2021, preprint, self-published Cochrane-style. F-Masks.PDF

The Health Harms and Risks of Face Masks

Leo Goldstein[1]

Introduction

In debates about the putative benefits of facemasks, the harms and risks receive very little consideration.

Originally, facemasks were proposed as a temporary measure. Also, people were expected to wear them only for short times. Now, face masks are being mandated, for undefined periods of time, and for many hours a day.  Very few studies of masks safety have been published since the beginning of masks wearing. The few studies that were published, and observational data shows very significant downsides of masks. That does not stop mask proponents from expanding the proposed mandates, not sparing even children.

Wearing facemasks might have been the first healthcare intervention in a half-century, introduced without any testing of its efficacy or safety. When proposing any new treatment or intervention, the top priority is to demonstrate safety; at least, to show that the risks are commensurate with its benefits. This was not done for facemasks. Continue reading The Health Harms and Risks of Face Masks

Oronasal Hygiene with PVP-I for COVID19

August 18, 2021, preprint.  PVPI.pdf

Oronasal Hygiene with PVP-I for COVID19

Leo Goldstein[1]

Bullet points
  • Mouth rinsing, gargling, and nasal irrigation with Povidone-Iodine (PVP-I) is safe and effective for prophylaxis, early treatment, and prevention of transmission of COVID-19
  • PVP-I has been used for decades as a broad-spectrum antiseptic in dentistry and otolaryngology, so its use for COVID-19 is not re-purposing
  • PVP-I has been widely used in India to prevent nosocomial transmission of COVID-19
  • In clinical trials, PVP-I was up to 90% in prevention hospitalizations and deaths from COVID-19
Abstract

Application of 0.5%-1.0% PVP-I solution to the nasal cavity, oral cavity, nasopharynx, and oropharynx, 2-4 times per day, is an excellent prophylaxis and adjuvant treatment of early COVID-19. Its use would also prevent or sharply decrease transmission of the virus from contagious persons. Povidone-Iodine (PVP-I) is available over the counter.

This is the conclusion from the available literature, including physicians’ recommendations. Continue reading Oronasal Hygiene with PVP-I for COVID19

Proposed Protocol for Self-Immunization against COVID-19

There is an update/improvement: Low Risk Natural Immunization against COVID-19

Proposed Protocol for Self-Immunization against COVID-19

PREPRINT, August 12-15, 2021; v3.  PDF  (archived v2)

Leo Goldstein [1]

Abstract

Prophylactically taking a small, less than preventative, dose of Hydroxychloroquine can improve an individual’s odds against COVID-19 upon accidental exposure. This allows the individual to lead a normal life and acquire broad natural immunity through a mild infection. The infection should be detected and terminated by appropriate anti–SARS-COV-2 medicines as soon as possible to minimize asymptomatic spread by that individual.

This is the proposed hypothesis. It is accompanied by a sample regimen suitable for a clinical trial. Continue reading Proposed Protocol for Self-Immunization against COVID-19

Asymptomatic Spread by Vaccinated Persons

Vaccinated persons present a higher coronavirus transmission risk than unvaccinated persons starting a few months from vaccination.

corrected

COVID-19 vaccines are injected intramuscularly and produce systemic immunity (Bleier, Ramanathan, and Lane 2021). They do not produce strong or long-lasting mucosal immunity (Tiboni, Casettari, and Illum 2021), which is another part of the natural immune response to infection, even an asymptomatic one. (Russell et al. 2020) provides a mucosal immunity review.

It was known from the start that the current COVID-19 vaccines do not provide sterilizing immunity. Another known fact is that even in vaccinated persons, the coronavirus can infect mucosal surfaces of the upper respiratory tract for at least a short time, where it can grow and be shed before being neutralized by the systemic immunity. It seemed not a major factor at the start of the vaccines roll out. Nevertheless, it was predicted that the rise of vaccine resistant and more infectious variants would create the problem of asymptomatic shedding from vaccinated persons (Goldstein 2021).

This has happened and was confirmed by direct measurements (Chia et al. 2021). This study found that vaccinated persons have the same initial viral load as unvaccinated ones, as tested by nasal swab. In the same group, the vaccinated persons were three times more frequently asymptomatic than unvaccinated ones. When symptomatic, vaccinated persons had fewer symptoms than unvaccinated persons, thus making the disease harder to notice. Continue reading Asymptomatic Spread by Vaccinated Persons

Bad Anti-HCQ Studies

(2020, updated in August 2021) Physician reports on hundreds of successfully treated, high-risk patients are not anecdotal evidence, even if they are not published in peer reviewed papers. Treating such reports as scientific evidence is long overdue. When researchers publish on this topic, failure to properly cite these reports is bad scientific conduct. If issues or questions arise, researchers can contact the practicing physicians directly and ask for any additional information needed. Researchers may choose to dismiss these reports and explain their reasons for doing so, but they cannot simply ignore them. Stating that such reports do not exist is scientific fraud. Continue reading Bad Anti-HCQ Studies

The Burden of Proof for Pandemic Treatment

This article was first published in TrialSiteNews behind a paywall.

We hear time and time again that one inexpensive COVID-19 treatment or another should not be used because there is not enough evidence for it. In hindsight, these arguments did not deserve serious consideration. For those who demand “evidence” behind a working treatment for a pandemic disease, no evidence would ever be enough.

Medical practice is like engineering in that both use science. I could make an analogy between the COVID-19 early antiviral treatment and airplanes 100 years ago. Opponents to airplanes would have had many more arguments against them than the opponents of ivermectin today. They would have made a long list of deadly airplane accidents, something that opponents of ivermectin for COVID-19 cannot do. They would have argued that the combustion engine is for cars, not for planes. Continue reading The Burden of Proof for Pandemic Treatment

Fraud and Mistakes in Reviews of IVM and HCQ for C19

Cochrane, once respected organization producing systematic reviews of peer-reviewed medical literature, issued a cherry-picked and biased review of Ivermectin for COVID-19, claiming not enough evidence. It is debunked by C19___ as Outdated very biased cherry-picking retrospective meta analysis …

That reminds the Cochrane’s HCQ review, published on Feb. 12, 2021. It was a similar piece of junk science and scientific fraud. This said, it contains three non-obvious methodological mistakes behind such non-positive reviews of Hydroxychloroquine and Ivermectin treatments for COVID-19, which some people might make unintentionally. Continue reading Fraud and Mistakes in Reviews of IVM and HCQ for C19

Guided Evolution of the Coronavirus

it is the vaccination that is creating the variants(Montagnier 2021)
Virologist Luc Montagnier, the Nobel Prize Winner in Medicine, 2008

Leo Goldstein, preprint,  v. 2021-06-30

Summary

SARS-COV-2 has surprised experts by its fast evolution and ability to evade vaccine-induced immunity while simultaneously increasing its infectivity. The explanation might lie in the extremely unlucky selection of S-protein (the spike) as the vaccine antigen. S-protein has a ridiculously small (~200 amino-acids) immunodominant region RBD, with epitopes mostly attracted to two sites of it. Further, the epitopes of the monomer S-protein from vaccines and trimer S-protein in the real coronavirus slightly differ.

The huge number of infected people and failure to treat patients with effective antivirals are also responsible for the fast the viral evolution. Vaccination with very narrow acting vaccines allows the coronavirus variants to escape vaccine elicited immunity. The use of vaccines and protocols that do not prevent infection and virus shedding contribute to the coronavirus escape from vaccine-elicited immunity. This process is self-accelerating – partially resistant variants infect vaccinated people in larger titers and shed for longer time, with a strong selection toward mutations toward escape from vaccine immunity. Continue reading Guided Evolution of the Coronavirus